Compare Novo Nordisk A/S (NVO) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Waste Management, Inc. — how do they compare? Novo Nordisk A/S trades at $38.39 (market cap $165.31B), while Waste Management, Inc. trades at $207.56 (market cap $83.98B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Waste Management, Inc. for 130 Days on average.
| NVO | WM | |
|---|---|---|
Market Cap | $165.31B | $83.98B |
Volume | 11,432,838 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $63.98 | $246.51 |
52-Week Low | $35.29 | $196.77 |
Typical Hold Time | 116 Days | 130 Days |
Enterprise Value | $179.56B | $106.78B |
Dividend Yield | 4.71% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Waste Management (WM) trades at $207.71, down 0.59% on the day, with a bullish technical signal despite bearish moving averages. The company reported revenue of $25.20 billion in 2025, with net income of $2.71 billion and a net margin of 10.74%. Recent earnings show mixed results, with a miss in Q4 2025 but beats in Q1 and Q2 2026. Analyst consensus is strongly positive with 54.29% buy ratings and no sell recommendations.
WM's outlook remains favorable due to steady revenue growth, strong cash flow, and a resilient business model. Key risks include elevated debt levels and competitive pressures. The stock offers a reliable dividend, with the next payment of $0.95 scheduled for September 25, 2026. Investors should weigh solid fundamentals against debt concerns for long-term holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
